Answers are grounded in this paper and cite their sources.
Background Routine hospital reports of multidrug-resistant organisms (MDROs) often count every isolate, whereas surveillance standards count each patient once. Infection prevention teams that work from monthly aggregate reports cannot remove duplicates themselves. We examined whether repeat isolates from the same patient distorted the apparent trend in MDRO detection and whether the distortion could be measured from aggregate counts alone. Methods We retrospectively analyzed 32 consecutive monthly surveillance reports (January 2024–August 2026) from a 1,200-bed general hospital in China, harmonized to one set of definitions. Repeat isolation was measured with the isolate-to-patient ratio (IPR; key MDRO isolates per MDRO-positive patient), which could be calculated from March 2025, and was monitored with a u -chart. For March–August 2025 versus March–August 2026 we compared isolate-based and patient-based MDRO densities per 1,000 patient-days and standardized the 2026 isolate-based proportion to the 2025 IPR. Results For January–August, the isolate-based MDRO proportion rose from 13.9% in 2024 to 19.4% in 2026 ( P for trend < 0.001). Between the two March–August periods, isolate-based density rose by 31% (rate ratio 1.31; 95% confidence interval [CI] 1.14–1.50) and patient-based density by 11% (rate ratio 1.11; 95% CI 0.93–1.33); the IPR rose from 1.60 to 1.89 (ratio 1.18; 95% CI 1.05–1.33). The IPR exceeded its upper control limit in May–July 2026, during an intensive care unit cluster of carbapenem-resistant Klebsiella pneumoniae (CRKP) in which three patients with bloodstream infection yielded 18 isolates in one month. Standardization to the 2025 IPR removed about half of the between-year difference in the isolate-based proportion (49%–59%, depending on the method). The rise in CRKP persisted in seasonally adjusted sensitivity analyses; the incidence of healthcare-associated infection caused by MDROs did not change measurably. Conclusions Counting every isolate exaggerated an increase in MDROs: about half of the apparent rise reflected more isolates per patient rather than more patients. Where patient-level deduplication is not at hand, the IPR can be calculated from two counts in a routine report, and charting it marks the months in which repeat culturing and clustering both need review. The approach was tested in one hospital and should be validated against patient-level first-isolate data.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: